Print

Morria Biopharmaceuticals Plc Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress  
6/15/2010 7:12:26 AM

LONDON & NEW YORK--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the 29th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London. The study‘s principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.
//-->